Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPOTLIGHT 204: BO-112 in Resectable Primary Low and High Risk Basal Cell Carcinoma
NCT06422936Phase 2Active, not recruiting
- Sponsor
- Highlight Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Oncolytic Viruses, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of nanoplexed poly I:C in basal cell carcinoma (BCC), sponsored by Highlight Therapeutics. Started May 2024; status: active, not recruiting.
02
Drugs
nanoplexed poly I:C
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT06422936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422936.